Karyopharm Therapeutics (KPTI) Competitors $7.14 -0.53 (-6.91%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$7.15 +0.01 (+0.14%) As of 05:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPTI vs. ANRO, RLMD, AVTE, GYRE, and SLDBShould you buy Karyopharm Therapeutics stock or one of its competitors? MarketBeat compares Karyopharm Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Karyopharm Therapeutics include Alto Neuroscience (ANRO), Relmada Therapeutics (RLMD), Aerovate Therapeutics (AVTE), Gyre Therapeutics (GYRE), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. KPTI vs. ANROKPTI vs. RLMDKPTI vs. AVTEKPTI vs. GYREKPTI vs. SLDBHow does Karyopharm Therapeutics compare to Alto Neuroscience?Karyopharm Therapeutics (NASDAQ:KPTI) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Do analysts prefer KPTI or ANRO? Karyopharm Therapeutics currently has a consensus target price of $17.17, indicating a potential upside of 140.43%. Alto Neuroscience has a consensus target price of $35.25, indicating a potential upside of 61.41%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Karyopharm Therapeutics is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Alto Neuroscience 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is KPTI or ANRO more profitable? Alto Neuroscience has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-129.02% N/A -120.29% Alto Neuroscience N/A -47.22%-38.81% Do insiders & institutionals hold more shares of KPTI or ANRO? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, KPTI or ANRO? Karyopharm Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Which has preferable valuation and earnings, KPTI or ANRO? Alto Neuroscience has lower revenue, but higher earnings than Karyopharm Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/AAlto NeuroscienceN/AN/A-$63.24M-$2.42N/A Does the media prefer KPTI or ANRO? In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 5 mentions for Alto Neuroscience. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Alto Neuroscience's score of -0.07 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alto Neuroscience 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKaryopharm Therapeutics beats Alto Neuroscience on 9 of the 16 factors compared between the two stocks.How does Karyopharm Therapeutics compare to Relmada Therapeutics?Relmada Therapeutics (NASDAQ:RLMD) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Do institutionals & insiders have more ownership in RLMD or KPTI? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, RLMD or KPTI? Relmada Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$57.38M-$1.09N/AKaryopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A Does the media prefer RLMD or KPTI? In the previous week, Relmada Therapeutics and Relmada Therapeutics both had 7 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Relmada Therapeutics' score of 0.10 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility and risk, RLMD or KPTI? Relmada Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Do analysts recommend RLMD or KPTI? Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 89.27%. Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 140.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is RLMD or KPTI more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -71.22% -64.46% Karyopharm Therapeutics -129.02%N/A -120.29% SummaryKaryopharm Therapeutics beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks.How does Karyopharm Therapeutics compare to Aerovate Therapeutics?Karyopharm Therapeutics (NASDAQ:KPTI) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Is KPTI or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-129.02% N/A -120.29% Aerovate Therapeutics N/A -90.19%-77.47% Do analysts rate KPTI or AVTE? Karyopharm Therapeutics presently has a consensus target price of $17.17, suggesting a potential upside of 140.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Karyopharm Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, KPTI or AVTE? Aerovate Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/AAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A Does the media favor KPTI or AVTE? In the previous week, Karyopharm Therapeutics had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 0 mentions for Aerovate Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Aerovate Therapeutics' score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Karyopharm Therapeutics Positive Aerovate Therapeutics Neutral Which has more risk and volatility, KPTI or AVTE? Karyopharm Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Do insiders & institutionals have more ownership in KPTI or AVTE? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryKaryopharm Therapeutics beats Aerovate Therapeutics on 10 of the 16 factors compared between the two stocks.How does Karyopharm Therapeutics compare to Gyre Therapeutics?Gyre Therapeutics (NASDAQ:GYRE) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment. Do analysts recommend GYRE or KPTI? Gyre Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 163.98%. Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 140.43%. Given Gyre Therapeutics' higher probable upside, research analysts clearly believe Gyre Therapeutics is more favorable than Karyopharm Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Does the media refer more to GYRE or KPTI? In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 6 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.08 beat Karyopharm Therapeutics' score of 0.55 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk and volatility, GYRE or KPTI? Gyre Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Which has stronger valuation and earnings, GYRE or KPTI? Gyre Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$116.59M5.36$5.03M-$0.09N/AKaryopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A Is GYRE or KPTI more profitable? Gyre Therapeutics has a net margin of -5.44% compared to Karyopharm Therapeutics' net margin of -129.02%. Gyre Therapeutics' return on equity of 3.13% beat Karyopharm Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-5.44% 3.13% 2.67% Karyopharm Therapeutics -129.02%N/A -120.29% Do institutionals and insiders have more ownership in GYRE or KPTI? 24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 10.0% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryGyre Therapeutics beats Karyopharm Therapeutics on 10 of the 17 factors compared between the two stocks.How does Karyopharm Therapeutics compare to Solid Biosciences?Solid Biosciences (NASDAQ:SLDB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Which has more volatility & risk, SLDB or KPTI? Solid Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Is SLDB or KPTI more profitable? Solid Biosciences has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Solid BiosciencesN/A -73.42% -61.13% Karyopharm Therapeutics -129.02%N/A -120.29% Which has better earnings & valuation, SLDB or KPTI? Solid Biosciences has higher earnings, but lower revenue than Karyopharm Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolid BiosciencesN/AN/A-$174.32M-$1.95N/AKaryopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A Do analysts prefer SLDB or KPTI? Solid Biosciences currently has a consensus price target of $16.36, indicating a potential upside of 151.36%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 140.43%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Solid Biosciences is more favorable than Karyopharm Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Does the media refer more to SLDB or KPTI? In the previous week, Solid Biosciences and Solid Biosciences both had 7 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Solid Biosciences' score of -0.14 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in SLDB or KPTI? 81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 13.6% of Solid Biosciences shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummarySolid Biosciences beats Karyopharm Therapeutics on 10 of the 14 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition ExportMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$173.82M$3.00B$6.25B$12.29BDividend YieldN/A1.98%2.80%5.30%P/E Ratio-0.4717.2220.6325.23Price / Sales1.11286.31554.9379.80Price / CashN/A56.3527.4837.30Price / Book-0.453.939.696.63Net Income-$196.04M$74.99M$3.56B$335.59M7 Day Performance-19.87%-4.47%-1.63%-1.20%1 Month Performance-17.07%-7.93%-2.59%-1.16%1 Year Performance39.18%29.34%30.08%28.10% Karyopharm Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.2592 of 5 stars$7.14-6.9%$17.17+140.4%+34.2%$173.82M$146.07MN/A380Earnings ReportANROAlto Neuroscience2.5965 of 5 stars$24.44+0.7%$35.13+43.7%+756.1%$775MN/AN/AN/AEarnings ReportAnalyst DowngradeRLMDRelmada Therapeutics2.7948 of 5 stars$7.36+0.5%$12.00+63.0%+1,275.3%$767.78MN/AN/A10Earnings ReportAVTEAerovate TherapeuticsN/A$25.81+6.6%N/A+218.0%$748.10MN/AN/A20Gap DownHigh Trading VolumeGYREGyre Therapeutics2.9311 of 5 stars$7.09-5.1%$17.00+139.8%-43.3%$724.54M$116.59MN/A40Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Alto Neuroscience Competitors Relmada Therapeutics Competitors Aerovate Therapeutics Competitors Gyre Therapeutics Competitors Solid Biosciences Competitors Aclaris Therapeutics Competitors CryoPort Competitors CytomX Therapeutics Competitors Sutro Biopharma Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
